Related Experiment Video

Updated: Jun 20, 2026

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents
07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Carvedilol may alleviate late cardiac remodelling following surgical ventricular restoration

Eiji Yoshikawa1, Akira Marui, Masaki Tsukashita

  • 1Department of Cardiovascular Surgery, Kyoto University, Graduate School of Medicine, Sakyo, Kyoto, 606-8507, Japan.

European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|August 21, 2009
PubMed

Insights

High-dose carvedilol effectively reduced left ventricular (LV) remodelling and improved diastolic function after surgical ventricular restoration (SVR) in rats. This suggests beta-blocker therapy may benefit patients post-SVR.

Area of Science:

  • Cardiology
  • Regenerative Medicine
  • Pharmacology

Background:

  • Surgical ventricular restoration (SVR) treats ischaemic cardiomyopathy and left ventricular (LV) aneurysm.
  • Post-SVR LV function improvement can be limited by ongoing LV remodelling.
  • Beta-blockers are known to prevent LV remodelling in heart failure, but their role after SVR is unclear.

Purpose of the Study:

  • To investigate the effects of carvedilol, a potent beta-blocker, on LV remodelling and function.
  • To assess carvedilol's efficacy in rats with myocardial infarction undergoing SVR.

Main Methods:

  • Rats with LV aneurysm post-myocardial infarction underwent SVR.
  • Post-SVR, rats received vehicle, low-dose (20 mg/kg/day), or high-dose (50 mg/kg/day) carvedilol for 4 weeks.
  • LV remodelling, systolic and diastolic function, fibrosis, and gene expression were evaluated.

Main Results:

  • High-dose carvedilol (50 mg/kg/day) significantly alleviated late LV remodelling.
  • No significant difference in LV systolic function was observed across groups.
  • LV diastolic function improved significantly with both low and high carvedilol doses.
  • High-dose carvedilol reduced myocardial fibrosis and expression of TGF-β1 and BNP.

Conclusions:

  • High-dose carvedilol effectively mitigated LV remodelling and diastolic dysfunction following SVR.
  • Carvedilol treatment was associated with reduced myocardial fibrosis.
  • Beta-adrenergic receptor blockade presents a potential adjuvant therapy for SVR patients.
Abstract

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...